Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Sep
Source: Bse
IOL Chemicals and Pharmaceuticals Limited (IOLCP)
Small CapIndustrials stocks · Small cap · NSE
IOL Chemicals and Pharmaceuticals Limited operates in API, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 05:56 pm ISTDetails
Quote19 Oct, 05:56 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:42 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Industrials P/E 26.2 (n=537)
Technical timing lens
Trend score and candlestick chart
57NeutralSMA20 +4.7% / mo · MACD −
Stock trend: 61
Sector RS: 50
Sector 3M: -6.3% vs Nifty 500 -5.6%
Industrials FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
IOLCPD candles · FIT view+105.5%Latest close ₹183.13 on 2026-10-19
Bar
-5.9%
RSI
41
MACD hist
-3.23
52W pos
74%
2026-10-19O ₹194.68H ₹194.68L ₹181.21C ₹183.13Vol 20.6L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
IOLCPNifty India ManufacturingNifty 500
- IOLCP
- +17.8%
- Nifty 500
- -5.6%
- Nifty India Manufacturing
- -5.8%
- Vs Nifty 500
- +23.4 pp
Chart stats
19 Oct 2026- From 52W high
- -18.2%
- 52W range position
- 74%
- ATR (14)
- 6.0%
- Volume vs 20D
- 0.69x
- Avg traded value
- ₹58.5 Cr
- 20D price channel
- ₹181.2 - ₹224
₹224
₹67.2 - ₹224
₹11
Latest completed session
20-session average
51.4% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · WATCHLIST36
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent100
Revenue +37.0% · PAT +88.2% YoY
Technical
Neutral57
Price trend and sector-relative-strength timing.
Valuation
Legacy model+27.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence80
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 100/100Rev +37% YoY · PAT +88% YoY · margin expansion · +22% QoQ · operating leverage
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹756 Cr | +37.0% | +22.1% |
| EBITDA | ₹103 Cr | +66.1% | +12.0% |
| Operating margin | 14.0% | +300 bps | -100 bps |
| PAT | ₹64 Cr | +88.2% | +20.8% |
| PAT margin | 8.5% | +231 bps | -9 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 34.20
- P/B
- 3.36
- EV/EBITDA
- 15.75
- Market Cap
- 6038.00Cr
Profitability
- ROE
- 8.41%
- ROCE
- 11.30%
- ROA
- 6.49%
- Dividend Y
- 0.49%
Growth (CAGR)
- Revenue 5Y
- 11.00%
- EPS 5Y
- 11.00%
- Revenue 3Y
- 2.00%
- EPS 3Y
- 2.00%
Balance Sheet
- Debt/Equity
- 0.08
- Interest Coverage
- 22.14×
- Altman Z
- 7.16
- Book Value
- 61.30
Cash Flow
- FCF Yield
- 0.26%
- FCF Positive Y
- 4/5
- OCF
- 214.00 Cr
- EPS TTM
- 5.72
Shareholding
- Promoter Hold
- 62.28%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 91%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 2,524+8.8% vs prev
Net Profit
₹ CrLatest: 138+36.6% vs prev
Return on Equity
%Latest: 7.7+28.3% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 41. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~4.5% over last month) — short-term momentum positive.
- RSI(14) at 41 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 18% off 52W high · 173% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
95
RS percentile
Stage 2 UptrendEstablished S2
1M return
-9.9%
3M return
+17.8%
6M return
+94.6%
1Y return
+97.6%
RS 1D
-1
RS 20D
-1
Sector rank
#2
Industry rank
#9
Stage evidence
- Price is 27.9% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +13.9%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
22 May 2026
S2 age
105 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 181.68-4.96%
RS vs Nifty 500182
Valuation & peers
U-Score 36 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 36 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation6/30
Growth8/25
Quality2/20
Balance Sheet12/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
-1
Raw sum
36
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
36/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 27.2%.
- Balance sheet contributes 12/15 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Quality is weaker at 2/20; verify the latest quarterly trend.
- Valuation is weaker at 6/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
34.2
PB
3.4
EV/EBITDA
15.8
ROE
8.4%
ROCE
11.3%
FCF Yield
0.3%
Debt/Equity
0.1
MoS
+27.2%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
36
Previous: 36
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+27.2%
Previous: +27.2%
Score history
12 stored score snapshots. Latest stored move: +2 points.
20 Oct 2026
v4.3-runtime-valuation
34
34
34
34
34
34
34
34
34
34
34
36
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹88.82
-106.2% MoS
Growth-justified P/E
44.0
Growth-justified Value
₹251.57
+27.2% MoS
PEG
4.62
Comparable companies
Peers
Business-comparable peers in Industrials — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
FCL
Small
Fineotex Chemical Limited
Specialty Chemicals
match 139
33
51.4
13.5%
-34%
WATCHLIST
GUJALKALI
Small
Gujarat Alkalies and Chemicals Limited
Specialty Chemicals
match 137
33
67.1
-0.1%
-1138%
WATCHLIST
TATVA
Small
Tatva Chintan Pharma Chem Limited
Specialty Chemicals
match 136
19
70.8
5.5%
-1191%
OVERVALUED
PREMEXPLN
Small
Premier Explosives Limited
Specialty Chemicals
match 135
46
107.0
18.8%
-183%
FAIR VALUE
APCOTEXIND
Small
Apcotex Industries Limited
Specialty Chemicals
match 135
38
83.3
24.4%
-300%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
IOL Chemicals and Pharmaceuticals Limited operates in API, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
80Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 90th percentile of the scored universe and 89th percentile within Industrials. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
99 docs text-extracted · 46 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
90th percentile
overall median 67 · Industrials: 89th pctile, median 68 · Small: 92nd pctile, median 66
Evidence depth
Financial-only
99 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
90
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
79
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 62.3%.
- ▸Promoter pledge is zero.
- ▸Promoter holding increased 9.7%.
- ▸FCF yield is positive at 0.3%.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching IOL Chemicals and Pharmaceuticals Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Sep - Business Update Conference Call to discuss the Company's recent business developments and strategic growth initiatives with investors and analysts
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Aug
Source: Bse
Credit rating
Announcement under Regulation 30 (LODR)-Credit Rating 1 Jul - CARE reaffirmed IOLCP's ratings: ₹200 crore long-term CARE A+; stable and ₹500 crore short-term CARE A1+.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026 from bse
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.